Elanco Animal Health (ELAN) Research & Development (2017 - 2026)

Elanco Animal Health has disclosed Research & Development across 10 years of filings, most recently posting $97.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $97.0 million, up 3.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $371.0 million (up 5.7% YoY), and the FY2025 annual result was $368.0 million, up 6.98% from the prior year.
• Research & Development came in at $97.0 million for Q1 2026 at Elanco Animal Health, up from $93.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $97.0 million in Q1 2026 to a low of $78.0 million in Q3 2022.
• The 5-year median for Research & Development is $86.0 million (2023), against an average of $85.7 million.
• Across the five-year window, Research & Development decreased 17.02% in 2022 and advanced 14.81% in 2025, its largest moves.
• Elanco Animal Health's Research & Development stood at $80.0 million in 2022, then dropped by 1.25% to $79.0 million in 2023, then increased by 2.53% to $81.0 million in 2024, then rose by 14.81% to $93.0 million in 2025, then grew by 4.3% to $97.0 million in 2026.
• The last three Research & Development figures came in at $97.0 million (Q1 2026), $93.0 million (Q4 2025), and $89.0 million (Q3 2025), per Business Quant data.